Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming
Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...
Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Open Label HLA Data ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...
Why anti-TNF drugs don't work for some kids with Crohn's disease
A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...
Greenwich LifeSciences reports progress in FLAMINGO-01 trial
STAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI), a clinical-stage biopharmaceutical company valued at $163 million, has announced the commencement of analysis on the open label HLA data ...